bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its...bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at the South Texas Veterans Health Care Systems’ Audie L. Murphy...bioAffinity Technologies to Report Third Quarter 2022 Financial Results
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m. ET to discuss its corporate and financial results for the...San Antonio cancer biotech follows IPO with patent win in China
San Antonio cancer biotech follows IPO with patent win in China NOVEMBER 2, 2022 As published in the San Antonio Business Journal By: By W. Scott Bailey – Senior Reporter, San Antonio Business Journal The People’s Republic of China has awarded a Certificate of Patent...